Author: Bio Space

Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV

January 28, 2022

Excision BioTherapeutics Inc. a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced the initiation of a first-in-human (FIH) Phase 1/2 clinical trial of EBT-101 in individuals living with human immunodeficiency virus type 1 (HIV). The FIH study is a multicenter, open-label, single ascending dose study designed to evaluate the […]

Manufacturing a Personalized Cellular Universe: 3D Bioprinting in the Biotech Industry

October 16, 2020

Tissues in the body work as a complex team of interconnected cells. For instance, the heart is comprised of contractile cardiomyocytes, along with a vast array of endothelial cells, immune cells and fibroblasts. Similarly, the liver includes hepatocytes, immune cells, endothelial cells and epithelial cells. Put in all the cellular players, and the team wins. […]